Skip to main content
. 2020 Oct 27;9(1):1832348. doi: 10.1080/2162402X.2020.1832348

Figure 2.

Figure 2.

PFS (months) to nivolumab treatment in mccRCC patients (a); mean value of plasmatic ICs levels in all nivolumab patients versus long-responders patients (>18 months) (b, c–f)